[go: up one dir, main page]

ME03540B - Transdermalne kompozicije ibuprofena i postupci za njihovu upotrebu - Google Patents

Transdermalne kompozicije ibuprofena i postupci za njihovu upotrebu

Info

Publication number
ME03540B
ME03540B MEP-2019-275A MEP2019275A ME03540B ME 03540 B ME03540 B ME 03540B ME P2019275 A MEP2019275 A ME P2019275A ME 03540 B ME03540 B ME 03540B
Authority
ME
Montenegro
Prior art keywords
ibuprofen
transdermal compositions
transdermal
compositions
Prior art date
Application number
MEP-2019-275A
Other languages
German (de)
English (en)
French (fr)
Inventor
Haigang Chen
Gareth Winckle
Christopher Riley
Original Assignee
Aponia Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47108054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03540(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aponia Laboratories Inc filed Critical Aponia Laboratories Inc
Publication of ME03540B publication Critical patent/ME03540B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MEP-2019-275A 2011-05-03 2012-05-03 Transdermalne kompozicije ibuprofena i postupci za njihovu upotrebu ME03540B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482058P 2011-05-03 2011-05-03
EP12779275.2A EP2704703B1 (en) 2011-05-03 2012-05-03 Transdermal compositions of ibuprofen and methods of use thereof
PCT/US2012/036366 WO2012151427A1 (en) 2011-05-03 2012-05-03 Transdermal compositions of ibuprofen and methods of use thereof

Publications (1)

Publication Number Publication Date
ME03540B true ME03540B (me) 2020-07-20

Family

ID=47108054

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-275A ME03540B (me) 2011-05-03 2012-05-03 Transdermalne kompozicije ibuprofena i postupci za njihovu upotrebu

Country Status (26)

Country Link
US (7) US9205041B2 (me)
EP (2) EP2704703B1 (me)
JP (1) JP5989095B2 (me)
KR (1) KR101926211B1 (me)
CN (1) CN103717213B (me)
AU (3) AU2012250664B2 (me)
BR (1) BR112013028435A2 (me)
CA (1) CA2835062C (me)
CL (1) CL2013003163A1 (me)
CO (1) CO6862148A2 (me)
CY (1) CY1122273T1 (me)
DK (1) DK2704703T3 (me)
EA (1) EA026697B1 (me)
ES (1) ES2749323T3 (me)
HR (1) HRP20191806T1 (me)
HU (1) HUE046750T2 (me)
LT (1) LT2704703T (me)
ME (1) ME03540B (me)
MX (1) MX365427B (me)
PE (2) PE20140936A1 (me)
PL (1) PL2704703T3 (me)
PT (1) PT2704703T (me)
RS (1) RS59484B1 (me)
SI (1) SI2704703T1 (me)
SM (1) SMT201900595T1 (me)
WO (1) WO2012151427A1 (me)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013028435A2 (pt) 2011-05-03 2017-01-24 Aponia Lab Inc composição para aplicação transdérmica
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
JP6632810B2 (ja) * 2015-03-31 2020-01-22 小林製薬株式会社 外用医薬組成物
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
BR112018070140A2 (pt) 2016-03-31 2019-02-05 Smartech Topical, Inc. sistema de distribuição
GB201609968D0 (en) 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
ES2982782T3 (es) * 2016-10-12 2024-10-17 Teikoku Seiyaku Kk Parche adhesivo a base de agua
US20190298688A1 (en) * 2016-11-21 2019-10-03 Vivier Canada Inc. Putrescine slow-release topical formulations
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
JP7025129B2 (ja) * 2017-05-17 2022-02-24 小林製薬株式会社 筋痙攣治療剤
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CA3082286A1 (en) 2017-12-04 2019-06-13 Johnson & Johnson Consumer Inc. Topical emulsion composition containing nonsteroidal anti-inflammatory drug
KR20190101140A (ko) * 2018-02-22 2019-08-30 동아제약 주식회사 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물
WO2019236374A2 (en) 2018-06-04 2019-12-12 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
CN109432061B (zh) * 2018-11-09 2020-10-30 北京德默高科医药技术有限公司 含有布洛芬或其结构类似物的多层经皮给药系统
MX2022005168A (es) 2019-11-06 2022-06-08 Smartech Topical Inc Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
CA3162675C (en) 2020-12-04 2023-09-26 Saori Kato Topical roflumilast formulation having antifungal properties
US11844753B2 (en) 2021-11-08 2023-12-19 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient
AU2022429340A1 (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
KR20250057103A (ko) 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
JPS59222409A (ja) 1983-06-01 1984-12-14 Nippon Redarii Kk 消炎鎮痛ゲル軟膏剤
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
DE3532562A1 (de) 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
EP0267321B1 (de) 1986-11-14 1990-02-28 MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG Ibuprofen enthaltendes Arzneimittel
US4916161A (en) 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5093133A (en) 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
IT1265001B1 (it) * 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
GB9404248D0 (en) 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
DE29714719U1 (de) 1997-08-19 1998-10-01 Starke, Olaf, 53940 Hellenthal Compaktdisc in Scheck oder Visitenkartenformat
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
JPH11199521A (ja) * 1997-12-26 1999-07-27 Lion Corp 皮膚外用剤
JP2000143540A (ja) * 1998-11-06 2000-05-23 Bristol Myers Squibb Co 非ステロイド系消炎鎮痛薬含有外用剤
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
FR2808685B1 (fr) * 2000-05-12 2004-10-08 Sanofi Synthelabo Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
RU2004113433A (ru) * 2001-10-04 2005-03-20 Макрокем Корпорейшн (Us) Эмульгаторы на основе солей ибупрофена и препаративные формы в виде крема, содержащие указанные вещества
US7816366B2 (en) * 2002-02-12 2010-10-19 Asymmetric Therapeutics, Llc Compositions and methods for treating and preventing dermatoses
WO2005051347A2 (en) 2003-10-30 2005-06-09 Dianne Elizabeth Marshall A simple process and formulation for making taste-­ masked ibuprofen liquid preparations and similar good­-tasting preparation of other pharmaceutically active or bitter, poor tasting compounds for the production of liquid preparations
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2006096360A1 (en) 2005-03-03 2006-09-14 Isw Group, Inc. Topical gels compositions
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
EP2222274B1 (en) 2007-11-29 2012-01-25 AllTranz Inc. Methods and compositons for enhancing the viability of microneedle pores
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
US20100055161A1 (en) 2008-08-27 2010-03-04 Dong June Ahn Hydrogel face mask for delivering skin care agents
US8604081B2 (en) * 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
BR112012012789A2 (pt) * 2009-11-27 2016-08-16 Nuvo Res Inc formulações de ibuprofeno tópicas
GB0921686D0 (en) * 2009-12-11 2010-01-27 Reckitt Benckiser Healthcare I Topical formulation
WO2011112875A2 (en) 2010-03-10 2011-09-15 Nuvo Research Inc. Foamable formulation
BR112013028435A2 (pt) 2011-05-03 2017-01-24 Aponia Lab Inc composição para aplicação transdérmica

Also Published As

Publication number Publication date
EA201391623A1 (ru) 2014-06-30
ES2749323T3 (es) 2020-03-19
RS59484B1 (sr) 2019-12-31
AU2019203188A1 (en) 2019-05-30
US20220387301A1 (en) 2022-12-08
CA2835062A1 (en) 2012-11-08
US20130005816A1 (en) 2013-01-03
US20180125779A1 (en) 2018-05-10
HRP20191806T1 (hr) 2020-01-10
US20160331678A1 (en) 2016-11-17
US9205041B2 (en) 2015-12-08
US10821071B2 (en) 2020-11-03
AU2012250664A1 (en) 2013-12-19
KR101926211B1 (ko) 2019-02-26
CY1122273T1 (el) 2020-11-25
SMT201900595T1 (it) 2019-11-13
US20240108569A1 (en) 2024-04-04
AU2012250664B2 (en) 2017-04-20
EP3560485A1 (en) 2019-10-30
CL2013003163A1 (es) 2014-07-04
EP2704703A1 (en) 2014-03-12
CN103717213B (zh) 2016-11-09
CO6862148A2 (es) 2014-02-10
US11419814B2 (en) 2022-08-23
WO2012151427A1 (en) 2012-11-08
BR112013028435A2 (pt) 2017-01-24
EP2704703A4 (en) 2014-12-03
PE20140936A1 (es) 2014-08-06
DK2704703T3 (da) 2019-10-14
KR20140041504A (ko) 2014-04-04
US20230248640A1 (en) 2023-08-10
PT2704703T (pt) 2019-10-25
SI2704703T1 (sl) 2019-12-31
US9849080B2 (en) 2017-12-26
JP2014513132A (ja) 2014-05-29
CA2835062C (en) 2019-08-13
NZ618259A (en) 2016-02-26
EA026697B1 (ru) 2017-05-31
AU2017204878A1 (en) 2017-08-03
CN103717213A (zh) 2014-04-09
US20210045999A1 (en) 2021-02-18
NZ703779A (en) 2016-10-28
PE20180399A1 (es) 2018-02-28
MX365427B (es) 2019-06-03
LT2704703T (lt) 2019-12-10
MX2013012832A (es) 2015-01-22
HUE046750T2 (hu) 2020-03-30
PL2704703T3 (pl) 2020-03-31
JP5989095B2 (ja) 2016-09-07
EP2704703B1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
ME03540B (me) Transdermalne kompozicije ibuprofena i postupci za njihovu upotrebu
CY2021010I2 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4-ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
EP2787985A4 (en) BIOCIDAL COMPOSITION AND METHODS OF USE
EP2699266A4 (en) COMPOSITIONS AND METHODS FOR STABILIZING ACTIVE INGREDIENTS
KR102096014B9 (ko) PCSK9 iRNA 조성물 및 그 사용 방법
PT2683406T (pt) Anticorpos anti-cd40 e utilização dos mesmos
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
EP2770980A4 (en) LOW SIZE LIPID NANOPARTICLES AND METHODS THEREOF
EP2670434A4 (en) TREATMENT OF TAUOPATHIES
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
EP2549865A4 (en) MRSA AND METHOD OF USE THEREOF
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
BR112014010450A2 (pt) composição e método
PL2704737T3 (pl) Terapeutyczne kompozycje nukleaz i sposoby
BR112014001991A2 (pt) certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
BR112014014213A2 (pt) agentes hemostáticos e método de utilização
EP3130583C0 (en) KYNURENINE-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
EP2802362A4 (en) LIQUID GEL CONCENTRATE COMPOSITIONS AND METHODS OF USE
BR112013014644A2 (pt) composição farmacêutica e complexo
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BR112014006291A2 (pt) composição e utilização da composição
DK2661274T3 (da) Sammensætninger og fremgangsmåder med aloepolysaccharider
EP2563347A4 (en) TRANSDERMAL PROPYNYLAMINOINDANE COMPOSITIONS